{"nctId":"NCT00248651","briefTitle":"Functional Dyspepsia Treatment Trial","startDateStruct":{"date":"2006-10"},"conditions":["Dyspepsia and Other Specified Disorders of Function of Stomach"],"count":292,"armGroups":[{"label":"Amitriptyline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Amitriptyline"]},{"label":"Escitalopram","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Escitalopram"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Amitriptyline","otherNames":["Elavil"]},{"name":"Escitalopram","otherNames":["Lexapro"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Normal esophagogastroduodenoscopy (EGD) (no esophagitis, Barrett's esophagus, cancer, erosions, or ulcer disease) within the past 5 years\n* Diagnosis of functional dyspepsia\n* Patients may have failed to adequately respond to antisecretory therapy in the past for functional dyspepsia to be suitable; a good response to antisecretory therapy, which remains first line therapy, suggests underlying gastroesophageal reflux disease (GERD).\n\nExclusion Criteria:\n\n* Any documented history of endoscopic esophagitis, or predominant heartburn or acid regurgitation, or these symptoms two or more times per week in the prior year, to exclude GERD.\n* Those who have had an adequate response to antisecretory therapy according to the physician interview, to exclude patients with disease easy to control with first line therapy or misdiagnosed GERD.\n* Any documented peptic ulcer disease.\n* Regular use of non-steroidal anti-inflammatory drugs (except long term low dose aspirin â‰¤ 325 mg / day)\n* Subjects undergoing psychiatric treatment, having a current history of drug or alcohol abuse, or currently taking psychotropic medication for depression or psychosis, or eating disorders\n* A history of abdominal surgery except appendectomy, cholecystectomy or hysterectomy, tubal ligations, bladder slings, and vasectomies\n* Subjects with concurrent major physical illness (including cardiac or liver disease, diabetes, inflammatory bowel disease, glaucoma, urinary retention, active thyroid disease, vasculitis, lactose intolerance explaining symptoms)\n* Subjects whose literacy skills are insufficient to complete self report questionnaires.\n* Pregnancy, or refusal to apply adequate contraceptive measures during the trial\n* Subjects currently on antidepressant therapy will be excluded.\n* Patients who score 11 or greater on the 7 questions related to depression of the Hospital Anxiety Depression Scale will be excluded. These patients will be encouraged to get follow up for depression.\n* All eligible patients over age 50 will have an EKG before randomization. Those found to have significant arrhythmias, conduction defects or a previous myocardial infarction on EKG will be excluded. Anyone with QT prolongation will be excluded.\n\nThe following concomitant medications will be prohibited during the trial:\n\n* Systemically acting cholinergics and anticholinergics (atropine, didinium bromide, propantheline)\n* Prokinetics (e.g., metoclopramide, tegaserod)\n* Macrolide antibiotics (e.g., erythromycin, azithromycin)\n* Aspirin (\\> 325 mg/day)\n* Spasmolytics (e.g., dicyclomine)\n* Antidepressants other than study medications\n* Serotonin enhancing drugs: monamine oxidase inhibitors, anticonvulsants, dextromethorphan.\n\nParticipants will be instructed to avoid grapefruit/grapefruit juice during the trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment","description":"The first two weeks of treatment were excluded to allow for establishment of steady state drug levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Gastric Emptying Half-Time (T1/2)","description":"The time for half of the ingested solids or liquids to leave the stomach.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":"43"},{"groupId":"OG001","value":"108","spread":"36"},{"groupId":"OG002","value":"115","spread":"40"}]}]}]},{"type":"SECONDARY","title":"Maximum Tolerated Volume by Nutrient Drink Test","description":"The nutrient drink test for meal-induced satiety had subjects drink 120 ml of ENSURE every four minutes. Satiety scores were measured on a scale graded 0-5 (1, no symptoms; 5, maximum satiety). When a score of 5 was reached, the maximum tolerated volume intake was measured. Abnormal satiety was defined as inability to consume \\> 800 ml of Ensure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"764","spread":"319"},{"groupId":"OG001","value":"823","spread":"391"},{"groupId":"OG002","value":"839","spread":"442"}]}]}]},{"type":"SECONDARY","title":"Dyspepsia-Specific Quality of Life","description":"The Nepean Dyspepsia Index (NDI) assessed quality of life. NDI scores are summarized into overall quality of life and 5 subscales: Interference, Knowledge/Control, Eating/Drinking, Sleep Disturbance, Work/Study. The scale consists of 25 items, yielding 5 sub-scales. Range 0-100, higher numbers indicate a greater quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.6","spread":null},{"groupId":"OG001","value":"82.8","spread":null},{"groupId":"OG002","value":"73.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"82.8","spread":null},{"groupId":"OG002","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.2","spread":null},{"groupId":"OG001","value":"76.2","spread":null},{"groupId":"OG002","value":"72.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"70.6","spread":null},{"groupId":"OG002","value":"64.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null},{"groupId":"OG001","value":"80.8","spread":null},{"groupId":"OG002","value":"76.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null},{"groupId":"OG001","value":"87.2","spread":null},{"groupId":"OG002","value":"79.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":97},"commonTop":["Drowsiness or Somnolence","Nausea/Vomiting","Dizziness","Headache","Anxiety"]}}}